Background
Blinatumomab is a bispecific T-cell engager (BiTE). It enables a patient’s T cells to recognize malignant B cells. A molecule of blinatumomab combines two binding sites: a CD3 site for T cells and a CD19 site for the target B cells. CD3 is part of the T cell receptor. Blinatumomab works by linking these two cell types and activating the T cell to exert cytotoxic activity on the target cell. CD3 and CD19 are expressed in both pediatric and adult patients, making blinatumomab a potential therapeutic option for both pediatric and adult populations.
Product Details
| Reactivity | Human |
| Specificity | Detects human CD19 and Human CD3ε in direct ELISA. This product is for research use only. |
| Source | CHO cell transient transfection |
| Sequence | Human CD19 scFv+Human CD3ε scFv+6xHis tag (N-terminus to C-terminus) |
| Purification | Affinity purified from CHO cell culture supernatant |
| Purity | >95% measured by SDS-PAGE. |
| Predicted MW | 54.1 kDa |
| Immunogen | Human CD19 and Human CD3ε |
| Endotoxin Level | <0.10 EU per 1 µg of the antibody by the LAL method |
| Formulation | 0.2 µm filtered solution in PBS |
| Reconstitution | Reconstitute at 0.5 mg/ml in sterile 1xPBS |
| Shipping | The product is shipped with polar packs. Upon receipt, store it immediately at -20 to -70°C |
| Storage Conditions | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. • 12 months from the date of receipt at -20 to -70°C as supplied. • 1 month at 2 to 8°C under sterile conditions |